ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

LIXTW Lixte Biotechnology Holdings Inc

0.05
0.00 (0.00%)
May 03 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.0402
Ask Price 0.1298
News -
Share Name Share Symbol Market Stock Type
Lixte Biotechnology Holdings Inc LIXTW NASDAQ Equity Warrant
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.05 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.05 0.05
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0  0.05 USD

Lixte Biotechnology Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.5M 2.25M - 0 -5.09M -2.26 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Lixte Biotechnology

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LIXTW Message Board. Create One! See More Posts on LIXTW Message Board See More Message Board Posts

LIXTW Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Lixte Biotech Holdings Inc is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company focuses on developing new treatments for human cancers for which therapies are urgently needed. It mainly designs drugs for which there are existing data suggesting any effect on altered pathways of the cancer cell and may be given safely to humans. The development program of the company includes drugs for the treatment of cancer, consisting of protein phosphatase inhibitors and histone deacetylase inhibitors.

Your Recent History

Delayed Upgrade Clock